BMO Capital Markets Focus on Healthcare Conference

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced that its chief executive officer, David McWilliams, will present at the upcoming BMO Capital Markets Focus on Healthcare Conference. The presentation is scheduled for 4:30 PM (Eastern Time) on Wednesday, December 6, 2006. The conference will be held from December 6-7, 2006 at the Millennium Broadway Hotel in New York City.

Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of Opexa’s web site at www.opexatherapeutics.com a few minutes prior to start time to download any necessary software.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company’s lead product, Tovaxin™, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type 1 diabetes. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Contacts

Opexa Therapeutics, Inc.
Lynne Hohlfeld, 281-719-3421
lhohlfeld@opexatherapeutics.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20061129005481&newsLang=en